Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Novavax earned a $125 million milestone payment after Sanofi dosed the first patients in its Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe using Novavax's Nuvaxovid. The trial pairs Sanofi's Efluelda/Fluzone High-Dose flu vaccine with Nuvaxovid in adults 60 and older; Novavax remains eligible for a further $75M milestone on manufacturing transfer (mid-2027) and $225M on a U.S. launch, plus royalties. The CEO noted the Sanofi partnership has generated over $1 billion in revenue for Novavax to date, and the combined flu-COVID market exceeds $10 billion.
Key figures
- Deal Value Usd
- 0
- Milestone earned usd
- 125000000
- Future milestone us launch usd
- 225000000
- Partnership revenue to date usd
- $1 billion
- Future milestone mfg transfer usd
- 75000000
- Combined flu covid market value usd
- $10 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.